Hints and tips:
...Jacobs said policymakers had a strong desire to maintain diversity in the Covid jab market by ensuring there was an alternative to the mRNA jabs provided by BioNTech/Pfizer and Moderna....
...Novavax’s Stanley Erck will be replaced by John C Jacobs, most recently chief executive at Harmony Biosciences, this month; CureVac’s Franz-Werner Haas will be succeeded by Alexander Zehnder, a Sanofi veteran...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...However, Ugur Sahin, head of BioNTech, who developed the vaccine now produced by Pfizer, struck a more positive note....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Pfizer similarly has all of its non-US production situated inside the bloc....
...Jacob Rees-Mogg, leader of the House of Commons, sought to link the rapid approval to Brexit. “We could only approve this vaccine so quickly because we have left the EU,” he said....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Others to be used include the BioNTech/Pfizer vaccine and possibly Russia’s Sputnik V and China’s Sinopharm....
...Its biggest push has been in coffee, with brands such as Keurig, Jacobs and Douwe Egberts. That has left it breathing down the neck of Nestlé, the world’s biggest hot drinks company....
...You Don’t Own Me: How Mattel v....
...JAB also owns, in partnership with Mondelez International, the Jacobs Douwe Egberts coffee business....
...“Hopefully there are another five of these [drugs] next year,” says Jacob Van Naarden, chief business officer of Loxo....
...“They’re definitely going to have to price it highly, or they wouldn’t have bought Kite for nearly $12bn,” says Maxim Jacobs, analyst at Edison, who estimates the treatment will go on sale at roughly $750,000...
...Jacob Sherkow, an associate professor at New York Law School, predicts that companies will eventually use similar arrangements to try to protect their medicines not just from the IPR process but also in...
...“If companies can get to the market quicker, that’s good for us and the whole system,” said Ian Read, chief executive of Pfizer....
...Pfizer rose 1.1 per cent to $31.05....
...Mr Lew’s third crackdown on tax inversion tie-ups immediately scuttled Pfizer’s migration to Europe earlier this month....
...Pfizer’s shares rose, as merger arbitrageurs likely closed out their short positions. The Treasury’s stance looks sensible....
...(CPI) Number of the day 73% v 28%The proportion of remaining delegates that Sanders would need to win in order to secure the nomination, compared to what Clinton needs....
...Pfizer was down 3 per cent at $32.29....
...“It’s a welcome mat for Pfizer to combine with Allergan and strip its earnings.”...
...Kenneth Jacobs, chief executive of Lazard, says: “The last cycle, toward the end, was skewed toward financial sponsor activity....
...In the UK, Emma Jacobs has been looking at those on the sharp end of online shopping – the delivery drivers....
International Edition